Clinical aspects and main forms of treatment for Fibromyalgia - Literature Review




Fibromyalgia; Pathophysiology; Pharmacological treatment.


Fibromyalgia is considered an incurable pathology and an idiopathic syndrome because its pathophysiology is not defined. The patient has symptoms such as chronic and generalized pain, tiredness and difficulty sleeping. It is considered frequent and its diagnosis is made by excluding other pathologies. Although there is still no effective treatment, pharmacological therapy helps patients to reduce symptoms. The purpose of this review was to analyze the pathophysiology involved in the development of fibromyalgia, as well as the pharmacological therapies, plants and medicinal compounds currently existing and studied for the treatment of this pathology, considering a period between 2009 and 2020. For that, the Scielo databases, Pubmed and Google Scholar were consulted. Thus, it can be seen that the existing pharmacological therapies mainly cover four classes of drugs, which are the antiepileptic drugs, tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs) and noradrenaline reuptake inhibitors, in addition to muscle relaxants, benzodiazepines, analgesic anti-inflammatories and herbal medicines. Despite the several published guidelines regarding the treatment of fibromyalgia, so far there is no fully effective therapy and in view of this the need for new specific drugs for this pathology is evident.


Ablin, J. N., & Buskila, D. (2013). Fibromyalgia syndrome–Novel therapeutic targets. Maturitas, 75 (4), 335-340.

Ammad, N. (2018). Comparative Efficacy of Pharmacological and Nonpharmacological Interventions in Managing Primary and Secondary Outcomes of Fibromyalgia Syndrome. Medical Student Research Journal,6 (1), 11-20.

Atsak, P., Guenzel, F. M., Kantar-Gok, D., Zalachoras, I., Yargicoglu, P., Meijer, O. C., Quirarte, G. L., Lobo, O.T., Schwabe, L., & Roozendaal, B. (2016). Glucocorticoids mediate stress-induced impairment of retrieval of stimulus-response memory. Psychoneuroendocrinology, 67 (1), 207-215.

Atzeni, F., Gerardi, M. C., Masala, I. F., Alciati, A., Batticciotto, A., & Sarzi-Puttini, P. (2017). An update on emerging drugs for fibromyalgia treatment. Expert opinion on emerging drugs, 22(4), 357-367.

Azevedo, P. M. (2018). A ciência da dor: Sobre fibromialgia e outras síndromes dolorosas persistentes e sobre a natureza humana. São Paulo: Editora Unesp Digital.

Barceló-Martinez, E., Gelves-Ospina, M., Navarro Lechuga, E., Allegri , R. F., Orozco-Acosta, E., Benítez-Agudelo, J. C., León-Jacobus, A., Román, N. F. (2018). Serum cortisol levels and neuropsychological impairments in patients diagnosed with Fibromyalgia. Actas Esp Psiquiatr, 46 (1), 1-11.

Benlidayi, I. C. (2019). Role of inflammation in the pathogenesis and treatment of fibromyalgia. Rheumatology international, 39(5), 781-791.

Bradley, L.A. (2009). Pathophysiology of fibromyalgia. The American Journal of Medicine 122 (12), S22-S30.

Calandre, E. P., Rico-Villademoros, F., & Slim, M. (2015). An update on pharmacotherapy for the treatment of fibromyalgia. Expert opinion on pharmacotherapy, 16(9), 1347-1368.

Casanueva, B., Rodero, B., Quintial, C., Llorca, J., & González-Gay, M. A. (2013). Short-term efficacy of topical capsaicin therapy in severely affected fibromyalgia patients. Rheumatology International, 33(10), 2665-2670.

Chinn, S., Caldwell, W., & Gritsenko, K. (2016). Fibromyalgia pathogenesis and treatment options update. Current Pain and Headache Reports, 20(4), 1-10.

Cooper, T. E., Derry, S., Wiffen, P. J., & Moore, R. A. (2017). Gabapentin for fibromyalgia pain in adults. Cochrane Database of Systematic Reviews, 1 (1), 1-28.

Derry, S., Wiffen, P. J., Haeuser, W., Mücke, M., Tölle, T. R., Bell, R. F., & Moore, R. A. (2017). Oral nonsteroidal anti‐inflammatory drugs for fibromyalgia in adults. Cochrane Database of Systematic Reviews, 1 (3), 1-39.

Di Franco, M., Lannuccelli, C., & Valesini, G. (2010). Neuroendocrine immunology of fibromyalgia. Annals of the New York Academy of Sciences, 1193 (1), 84-90.

Dursun, M., Besiroglu, H., Tellioglu, E., Saglam, Y., & Ortac, M. (2019). Association Between Sexual Dysfunction, Sleep Impairment and Depression in Women with Fibromyalgia. Sexuality and Disability, 1 (1), 1-9.

Faria, P. C.; Silva, L. R. T.; Fonseca, A. C. S.; Silva, R. V.; Meireles, C.; Pernambuco, A. P. (2014). Fibromialgia: diagnóstico, fisiopatologia e tratamentos. Conexão ciência (Online), 9 (1), 01-19.

Fischer, S., Doerr, J. M., Strahler, J., Mewes, R., Thieme, K., & Nater, U. M. (2016). Stress exacerbates pain in the everyday lives of women with fibromyalgia syndrome - the role of cortisol and alpha-amylase. Psychoneuroendocrinology, 63 (1), 68-77.

Freitas, R. P.A, de Andrade, S. C., Spyrides, M. H. C., Micussi, M. T. A. B. C., & de Sousa, M. B. C. (2017). Impacto do apoio social sobre os sintomas de mulheres brasileiras com fibromialgia. Revista Brasileira de Reumatologia, 57(3), 197-203.

Gaskell, H., Moore, R. A., Derry, S., & Stannard, C. (2016). Oxycodone for pain in fibromyalgia in adults. Cochrane Database of Systematic Reviews, 1 (9), 1-22.

Gavi, M. B. R. D. O., Coser, P. H. P., Macedo, D. C. F., Oliveira, C. G. T. D., & Silva, L. C. G. D. (2018). O uso do Mini-Exame do estado Mental colabora no tratamento da fibromialgia. Ciências & Cognição, 23 (1), 108-116.

Gilron, I., Chaparro, L. E., Tu, D., Holden, R. R., Milev, R., Towheed, T., DuMerton-Shore, D, & Walker, S. (2016). Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial. Pain, 157(7), 1532-1540. doi: 10.1097 / j.pain.0000000000000558

Glass, J. M., Williams, D. A., Fernandez-Sanchez, M. L., Kairys, A., Barjola, P., Heitzeg, M. M., Clauw, D.J, & Schmidt-Wilcke, T. (2011). Executive function in chronic pain patients and healthy controls: different cortical activation during response inhibition in fibromyalgia. The journal of pain, 12(12), 1219-1229.

Halpern, R., Shah, S. N., Cappelleri, J. C., Masters, E. T., & Clair, A. (2016). Evaluating guideline‐recommended pain medication use among patients with newly diagnosed fibromyalgia. Pain Practice, 16 (8), 1027-1039.

Häuser, W., Ablin, J., Fitzcharles, M. A., Littlejohn, G., Luciano, J. V., Usui, C., & Walitt, B. (2015). Fibromyalgia. Nature reviews Disease primers, 1(1), 1-16.

Kaouk, S., Wilke, W. S., & Gota, C. E. (2018). Characteristics of fibromyalgia patients prescribed opioid medications: data from the Cleveland clinic fibromyalgia registry. International Journal of Clinical Rheumatology, 13(2), 82-93.

Kato, K., Sullivan, P. F., Evengård, B., & Pedersen, N. L. (2009). A population-based twin study of functional somatic syndromes. Psychological medicine, 39(3), 497-505. Doi: 10.1017 / S0033291708003784

Kia, S., & Choy, E. (2017). Update on treatment guideline in fibromyalgia syndrome with focus on pharmacology. Biomedicines, 5(2), 20.

Klein, C.P., Rodrigues Cintra, M., Binda, N., Montijo Diniz, D., Gomez, M. V., Souto, A. A., & Souza, A. H. (2016). Coadministration of Resveratrol and Rice Oil Mitigates Nociception and Oxidative State in a Mouse Fibromyalgia-Like Model. Pain Research & Treatment, 1(1), 1-10.

Lauche, R., Cramer, H., Häuser, W., Dobos, G., & Langhorst, J. (2015). A systematic overview of reviews for complementary and alternative therapies in the treatment of the fibromyalgia syndrome. Evidence-Based Complementary and Alternative Medicine, 1 (1), 1-10.

Lawson, K. (2016). Potential drug therapies for the treatment of fibromyalgia. Expert opinion on investigational drugs, 25(9), 1071-1081.

Littlejohn, G., & Guymer, E. (2017). Modulation of NMDA receptor activity in fibromyalgia. Biomedicines, 5(2), 15.

Loggia, M. L., Berna, C., Kim, J., Cahalan, C. M., Gollub, R. L., Wasan, A. D., Harris, R E., Edwards, R.R., & Napadow, V. (2014). Disrupted brain circuitry for pain‐related reward/punishment in fibromyalgia. Arthritis & rheumatology, 66(1), 203-212.

Marlow, N. M., Simpson, K. N., Vaughn, I. A., Jo, A., Zoller, J. S., & Short, E. B. (2017). Healthcare Costs and medication adherence among patients with fibromyalgia: combination medication vs. duloxetine, milnacipran, venlafaxine, and pregabalin initiators. Pain Practice, 18(2), 154-169.

Marques, A. P., Santo, A. D. S. D. E., Berssaneti, A. A., Matsutani, L. A., & Yuan, S. L. K. (2017). Prevalence of fibromyalgia: literature review update. Revista Brasileira de Reumatologia, 57(4), 356-363.

Martínez, S. S., Almela, Z. M., Carrasco, P. C., González, B. E., Moya, A. L., & Redolat, I. R. (2011). Hormonas, Estado de ánimo y función cognitiva. Ed. Delta. Madrid: España, 215-222.

Matarín Jimenez, T. M., Fernández‐Sola, C., Hernández‐Padilla, J. M., Correa Casado, M., Antequera Raynal, L. H., & Granero‐Molina, J. (2017). Perceptions about the sexuality of women with fibromyalgia syndrome: A phenomenological study. Journal of Advanced Nursing, 73(7), 1646-1656.

Mease, P. J., Dundon, K., & Sarzi-Puttini, P. (2011). Pharmacotherapy of fibromyalgia. Best Practice & Research Clinical Rheumatology , 25 (2), 285-297.

Metyas, S., Rezk, T., Arkfeld, D., & Leptich, T. (2017). Autoinflammation and immunomodulation in inflammatory fibromyalgia syndrome-a review. Current rheumatology reviews, 13(2), 98-102.

Montserrat-de la Paz, S., Garcia-Gimenez, M. D., Quilez, A. M., De la Puerta, R., & Fernandez-Arche, A. (2018). Ginger rhizome enhances the anti-inflammatory and anti-nociceptive effects of paracetamol in an experimental mouse model of fibromyalgia. Inflammopharmacology, 26 (4), 1093-1101.

Morales, K. O., Passarelli, B. S., Casimiro, E. F., Pereira, J. C., Deliberato, P. C. P., & dos Santos, B. R. M. (2019). O uso da técnica manual shiatsu no alívio dos sintomas decorrentes da fibromialgia. Unisanta Health Science, 3(1), 1-17.

Oliveira Júnior, J. O. D., & Almeida, M. B. D. (2018). The current treatment of fibromyalgia. BrJP, 1(3), 255-262.

Parkitny, L., & Younger, J. (2017). Reduced pro-inflammatory cytokines after eight weeks of low-dose naltrexone for fibromyalgia. Biomedicines, 5(2), 16.

Pernambuco, A. P., Schetino, L. P., Carvalho, L. S. C., & Reis, D. A. (2016). Involvement of oxidative stress and nitric oxide in fibromyalgia pathophysiology: a relationship to be elucidated. Journal of Pain & Relief, 5 (3), 1-7.

Pereira, A. S., Shitsuka, D. M., Parreira, F. J., & Shitsuka, R. (2018). Metodologia da pesquisa científica. [E-book]. Santa Maria. Ed. UAB/NTE/UFSM.

Puretić, M. B, & Demarin, V. (2012). Neuroplasticity mechanisms in the pathophysiology of chronic pain. Acta Clinica Croatica, 51(2), 425-429.

Quilez, A. M., Montserrat-de la Paz, S., Fernandez-Arche, A., De la Puerta, R., & Garcia-Gimenez, M. D. (2018). Diets supplemented with Annona muricata improve the symptoms of fibromyalgia. PharmaNutrition, 6(3), 81-84.

Rizzi, M., Cristiano, A., Frassanito, F., Macaluso, C., Airoldi, A, & Sarzi-Puttini, P. (2016). Sleep disorders in fibromyalgia syndrome. Journal of Pain & Relief, 5 (2), 1-5. DOI: 10.4172/2167-0846.1000232

Sagy, I., Bar-Lev Schleider, L., Abu-Shakra, M., & Novack, V. (2019). Safety and efficacy of medical cannabis in fibromyalgia. Journal of clinical medicine, 8(6), 1-12.

Salvat-Pujol, N., Labad, J., Urretavizcaya, M., de Arriba-Arnau, A., Segalàs, C., Real, E., Ferre, A., Cresco, J.M., Jiménez-Murcia, S., Soriano-Mas, C., Menchón, J. M., & Soria, V. (2017). Hypothalamic-pituitary-adrenal axis activity and cognition in major depression: the role of remission status. Psychoneuroendocrinology, 76 (1), 38-48.

Sarzi-Puttini, P., Atzeni, F., Di Franco, M., Buskila, D., Alciati, A., Giacomelli, C., Rossi, A., & Bazzichi, L. (2012). Dysfunctional syndromes and fibromyalgia: a 2012 critical digest. Clin Exp Rheumatol, 30(6 Suppl 74), 143-151.

Schafranski, M. D., Merlini, A. B., de Oliveira Prestes, A. L., Ribeiro, B., da Silva Geraldino, J., & Gauer, M. F. (2013). Eficácia dos antidepressivos na fibromialgia: uma análise crítica a partir de dados raramente encontrados nos artigos científicos. Publicatio UEPG: Ciências Biológicas e da Saúde, 19(2), 131-141.

Shakiba, M., Moazen-Zadeh, E., Noorbala, A. A., Jafarinia, M., Divsalar, P., Kashani, L., Shahmansouri, N., Tafakhori, A., Bayat, H., & Akhondzadeh, S. (2018). Saffron (Crocus sativus) versus duloxetine for treatment of patients with fibromyalgia: A randomized double-blind clinical trial. Avicenna journal of phytomedicine, 8(6), 513-523.

Sharma, S., & Kochhar, K. P. (2019). Use of medicinal plants in treatment of fibromyalgia. International Journal of Pharmaceutical and Biological Science Archive, 7(5), 7-11.

Souza Nascimento, S., Santana, J. M., Nampo, F. K., Ribeiro, Ê. A. N., Silva, D. L., Araújo-Júnior, J. X., Almeida, J.R.G.S., Bonjardim, L.R., Souza Araujo, A.A., & Quintans-Júnior, L. J. (2013). Efficacy and safety of medicinal plants or related natural products for fibromyalgia: a systematic review. Evidence-Based Complementary and Alternative Medicine, 1 (1), 1-11.

Souza Nascimento, S., Serafini, M. R., de Santana, J. M., & Quintans Junior, L. J. (2012). Utilização de plantas medicinais no tratamento da fibromialgia: uma prospecção tecnológica. Revista GEINTEC-Gestão, Inovação e Tecnologias, 3(1), 068-075. DOI:

Souza, J. B. D., & Perissinotti, D. M. N. (2018). The prevalence of fibromyalgia in Brazil–a population-based study with secondary data of the study on chronic pain prevalence in Brazil. BrJP, 1(4), 345-348.

Steudte-Schmiedgen, S., Wichmann, S., Stalder, T., Hilbert, K., Muehlhan, M., Lueken, U., & Beesdo-Baum, K. (2017). Hair cortisol concentrations and cortisol stress reactivity in generalized anxiety disorder, major depression and their comorbidity. Journal of psychiatric research, 84 (1), 184-190.

Tanwar, M. S., Jain, S., Kumar, U., Dada, R., & Bhatia, R. (2016). Reproductive Hormones in Pathophysiology of Fibromyalgia Syndrome. Indian Obstetrics and Gynaecology, 6(3), 35-42.

Torquato, A. C., Dias, F. A., Wachholz, L. B., & Nesello, L. Â. N. (2019). Comparação entre os resultados obtidos por diferentes métodos de avaliação da composição corporal em mulheres com síndrome de fibromialgia. RBONE-Revista Brasileira de Obesidade, Nutrição e Emagrecimento, 13(77), 103-110.

Tsilioni, I., Russell, I. J., Stewart, J. M., Gleason, R. M., & Theoharides, T. C. (2016). Neuropeptides CRH, SP, HK-1, and inflammatory cytokines IL-6 and TNF are increased in serum of patients with fibromyalgia syndrome, implicating mast cells. Journal of Pharmacology and Experimental Therapeutics, 356(3), 664-672. DOI:

Tzeng, N. S., Chung, C. H., Liu, F. C., Chiu, Y. H., Chang, H. A., Yeh, C. B., Huang, S., Lu, R., Yeh, H., Kao, Y., Chiang, W. S., Tsao, C.H., Wu, Y.F., Chou, Y.C., Lin, F.H., & Chien, W.C. (2018). Fibromyalgia and risk of dementia—a nationwide, population-based, cohort study. The American Journal of the Medical Sciences, 355(2), 153-161.

Vilaça, M. M. O., Santos Lima, K. B., Alencar, E. V. M., da Conceição Machado, K., & Conceição Machado, K. (2020). New fibromyalgia treatment medicinal products. Research, Society and Development, 9(3), 1-14. DOI:

Welsch, P., Bernardy, K., Derry, S., Moore, R. A., & Häuser, W. (2018). Mirtazapine for fibromyalgia in adults. Cochrane Database of Systematic Reviews, 1 (8), 1-6.

White, C., Kwong, W. J., Armstrong, H., Behling, M., Niemira, J., & Lang, K. (2018). Analysis of Real-World Dosing Patterns for the 3 FDA-Approved Medications in the Treatment of Fibromyalgia. American health & drug benefits, 11(6), 293-301.

Wolfe, F., Walitt, B., Perrot, S., Rasker, J. J., & Häuser, W. (2018). Fibromyalgia diagnosis and biased assessment: Sex, prevalence and bias. PLoS One, 13(9), e0203755.

Wu, Y. L., Chang, L. Y., Lee, H. C., Fang, S. C., & Tsai, P. S. (2017). Sleep disturbances in fibromyalgia: A meta-analysis of case-control studies. Journal of psychosomatic research, 96 (1), 89-97.

Yolanda Castaño, M., Garrido, M., Rodríguez, A. B., & Gómez, M. Á. (2019). Melatonin Improves Mood Status and Quality of Life and Decreases Cortisol Levels in Fibromyalgia. Biological research for nursing, 21(1), 22-29.



How to Cite

COSTA, S. M. L. .; SILVA, M. P. M. P. e .; PINTO, L. P. .; SOUSA, D. L. R. . Clinical aspects and main forms of treatment for Fibromyalgia - Literature Review. Research, Society and Development, [S. l.], v. 9, n. 11, p. e729119495, 2020. DOI: 10.33448/rsd-v9i11.9495. Disponível em: Acesso em: 17 sep. 2021.



Review Article